Prof. James C. S. Chim

The University of Hong Kong, China

Email: jcschim@hkucc.hku.hk

Qualifications

2006 Ph.D., University of Hong Kong, HK, China

2002 M.D., University of Hong Kong, HK, China

1986 M.B. & Ch.B., Chinese University of Hong Kong, HK, China

Publications (Selected)

1. Chim CS, et al. Nasal NK-cell lymphoma: Long-term treatment outcome and validity of the IPI Index. Blood 2004, 103: 216-221.
2. Chim CS, et al. p15 and p16 promotor methylation in acute promyelocytic leukaemia. J Clin Oncol, 19: 2033-2040, 2001.
3. Chim CS, et al.SOCS1 and SHP1 Hypermethylation in Multiple Myeloma: Implications for Epigenetic Activation of the Jak/STAT pathway. Blood 2004; 103:4630-4635.
4. Chim CS, et al. Long-term outcome of 231 patients with Essential Thrombocythemia: Prognostic factors for bleeding, thrombosis, myelofibrosis and leukaemia. Archives Int Med, 2005, 165: 2651-2658.
5. Li Z, Chim JC, Yang M, Ye J, Wong BC, Qiao L. Role of PCDH10 and its hypermethylation in human gastric cancer. Biochim Biophys Acta. 2011 Dec 20.
6. Chim CS, Wan TS, Wong KY, Fung TK, Drexter HG, Wong KF. Methylation of miR-34a, miR-34b/c, miR-124a and miR-203 in Ph-negative myeloproliferative neoplasms. J Transl Med, 2011 Nov 14;9(1):197.
7. KY Wong, Rita LH Yim, CC So, DY Jin, Raymond Liang, CS Chim. Epigenetic inactivation of the MIR34B/C in multiple myeloma.  Blood, 2011; 118: 5901-5904.
8. Morgan G; Johnsen HE; Goldschmidt H; Palumbo A; Cavo M; Sonneveld P; San Miguel JF; Chim CS; Browne PV; Einsele H; Waage A; Hajek R; Ludwig H; Turesson I; Spencer A; Hemminki K. MAGIC (MyelomA Genetics International Consortium).  Leuk Lymphoma, 2011.
9. Hwang YY, Loong F, Chung LP, Chim CS. Atypical Burkitt’s lymphoma transforming from follicular lymphoma. Diagnostic Pathol, 2011.
10. Kwan-Yeung Wong, Raymond Liang, Chi-Chiu So, Yanting Qi, Dong-Yan Jin, Joseph F. Costello, Chor-Sang Chim. Epigenetic silencing of miR-203 in multiple myeloma. Br J Haematol, Sep; 154(5): 569-78.
11. Bing Zou, C.S. Chim, Roberta Pang, Hui Zeng, Yun Dai, Rongxin Zhang, Colin S.C. Lam, Victoria P.Y. Tan, Ivan F.N. Hung, Huiyao Lan, Benjamin C.Y. Wong. Mol Carcinogenesis, Zou B, Chim CS, Pang R, Zeng H, Dai Y, Zhang R, Lam CS, Tan VP, Hung IF, Lan HY, Wong BC. XIAP-associated factor 1 (XAF1), a novel target of p53, enhances p53-mediated apoptosis via post-translational modification. Mol Carcinog. 2011 Jun 15. doi: 10.1002/mc.20807.
12. Gill H, Chim CS, Au WY, Loong F, Tse E, Leung AY, Kwong YL. Non-gastric marginal zone B cell lymphoma: clinicopathologic features and treatment results. Ann Hematol. 2011 Apr 8.
13. KY Wong, CC So, F Loong, LP Chung, WWL Lam, R Liang, DY Jin, CS Chim. Epigenetic Inactivation of the miR-124-1 in Haematological Malignancies. PloS ONE. 2011 Apr 22;6(4):e19027.
14. Chim CS, Wong KY, Leung CY, Chung LP, Hui PK, Chan SY, Yu L. Epigenetic inactivation of the miR-203 in haematological malignancies.  J Cell Mol Med, 2011 Feb 15. [Epub ahead of print].
15. Chim CS. Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidlomide/dexamethasone in transplant eligible patients. J Transl Med. 2010, 8: 124.
16. Wong KY, Yu L, Chim CS. DNA methylation of tumor suppressor microRNA genes: a lesson from miR-34 family. Epigenomics, February 2011, 3(1): 83-92.
17. Ma ATW, Lo R, Cheng S, Chim CS. Multiple Myeloma Presenting as Interstitial Lung Disease. J Clin Oncol, 2010, Dec 6, [Epub ahead of print].
18. Chim CS, Wan TS, Fung TK, Wong KF. Methylation of TET2, CBL and CEBPA in Ph-negative myeloproliferative neoplasms. J Clin Pathol.2010, 63(10):942-6.
19. Chim CS, Lie AKW, Chan EYT1, Leung YY1, Cheung SCW2, Chan SYT, Liang R, Kwong YL. A staged approach with vincristine, adriamycin and dexamethasone followed by bortezomib, thalidomide and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma. Annals Hematol, 2010 Oct; 89(10): 1019-27.
20. Hu XT, Chen YW Chen, Liang CT, Au WY, Wong KY, Wan SK, Wong LY, Shen L, Chan KK, Guo T, Chu KM, Tao Q, Chim CS, Loong F, Choi WL, Lu L, So CC, Chan LC, Kwong YL, Liang R, CD44 activation in mature B-cell malignancies by a novel recurrent IGH translocation.  Srivastava1 G. Blood, 2010, 115(12):2458-61.
21. CS Chim, KY Wong, Y Qi, Loong F, WL Lam, LG Wong, Jin DY, Costello JF, Liang R., Epigenetic inactivation of the miR-34a in hematological malignancies. Carcinogenesis, 2010, 31(4):745-50.
22. Chim CS, Fung TK, Liang R. Methylation of cyclin-dependent kinase inhibitors, XAF1, JUNB, CDH13 and soluble Wnt inhibitors in Essential Thrombocythemia. J Clin Pathol, 2010, Jun; 63(6): 518-21.
23. Chim CS, Sim JP, Chan CC, Kho BC, Chan JC, Wong LG, Law M, Liang R, Kwong YL. Impact of JAK2V617F mutation on thrombosis and myeloid transformation in essential thrombocythemia: a multivariate analysis by Cox regression in 141 patients. Haematology, 2010 Aug; 15(4): 187-92.
24. Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, Niesvizky R, Morgan G, Comenzo R, Sonneveld P, Kumar S, Hajek R, Giralt S, Bringhen S, Anderson KC, Richardson PG, Cavo M,Davies F, Blad J, Einsele H, Dimopoulos MA, Spencer A, Dispenzieri A, Reiman T, Shimizu K, Lee JH, Attal M, Boccadoro M, Mateos M, Chen W, Ludwig H, Joshua D, Chim J, Hungria V, Turesson I, Durie BG, Lonial S., International Myeloma Working Group guidelines for the management of multiple, myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia, 2009 Oct;23(10):1716-30.